Navigation Links
WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening
Date:12/7/2009

SHANGHAI, Dec. 7 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today it has purchased a Labcyte POD(TM) 810 plate assembler equipped with an Echo(R) 555 acoustic liquid handler for its work in high- throughput screening and secondary screening. WuXi PharmaTech joins the growing number of pharmaceutical companies worldwide that have incorporated the POD system into their compound management and HTS processes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

"With this technology WuXi will remain the leader in pharmaceutical outsourcing-this demonstrates our continuous efforts to build both capabilities and capacity to help our partners to improve the success of discovery and shorten development time," commented Dr Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.

"Acoustic liquid handling is clearly the method of choice in drug discovery," said Dr. Qiang Lu, Vice President of Discovery Biology of WuXi PharmaTech. "We are very pleased to incorporate the POD 810 into our systems. It will make our drug discovery efforts significantly more productive while it reduces cost through the elimination of disposable plastic tips. We know that acoustic liquid handling will significantly improve the quality of the data we generate. We are looking forward to a continuing relationship with Labcyte."

The POD 810 plate assembler, a walk-away, out-of-the-box solution, transforms any Echo acoustic liquid handler into a Plates-On-Demand instrument. The POD system is controlled by its revolutionary Intellectual Scheduler with built-in intelligence to automatically adjust workflow to maximize productivity.

"The POD platform is uniquely positioned to advance method standardization across global sites," said Mark Fischer-Colbrie, president and CEO of Labcyte Inc. "It eliminates the unnecessary delays associated with customized integration."

"We are very pleased WuXi PharmaTech decided to acquire a Labcyte POD system," said Sanger Chang, General Manager of Tekon Biotech. "Our exclusive relationship with Labcyte is further validation of our efforts to be the leading supplier of instrument systems for pharmaceutical research to the Chinese market by providing the highest level of technical support and service."

    For more information, please contact:

    WuXi PharmaTech (Cayman) Inc.

     Ronald Aldridge (for investors)
     Director of Investor Relations
     Tel:   +1-201-585-2048
     Email: ir@wuxiapptec.com

     Stephanie Liu (for the media)
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +86-21-5046-4362
     Email: pr@wuxiapptec.com

SOURCE WuXi PharmaTech (Cayman) Inc.


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
2. WuXi PharmaTech Announces Second Quarter 2007 Results
3. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
4. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
5. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
6. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
7. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
8. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
9. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
10. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
11. WuXi PharmaTech Completes Acquisition of AppTec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology:
(Date:6/9/2016)... innovation leader in attendance control systems is proud to announce the introduction of fingerprint ... sure the right employees are actually signing in, and to even control the opening ... ... ... Photo ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
Breaking Biology News(10 mins):